NOXOPHARM LIMITED - Announcements

Market Cap $19.28M Add to my watchlist

Healthcare Biotechnology

Noxopharm Limited is an Australia-based biotechnology company. The Company is engaged in... Noxopharm Limited is an Australia-based biotechnology company. The Company is engaged in the discovery and development of treatments for cancer and inflammation. The Company has three active drug development programs: its clinical drug candidate Veyonda, plus two technology platforms, Chroma (oncology) and Sofra (inflammation and autoimmunity), which provide the basis for the active development of a growing pipeline of drugs. Veyonda (Idronoxil) is an adjuvant therapy in chemotherapy and radiotherapy in the treatment of late-stage cancers. The Chroma drug candidates have bioactive properties, which it is exploring primarily in the anti-cancer space. Its Sofra platform is centered around short nucleic acid sequences called oligonucleotides, which can act on specific cell receptors to stop inflammation, which is a source of various debilitating and lethal diseases. It is also conducting a dose escalation and dose expansion study of NOX66 in the treatment of COVID-19 infection.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

NOX	March 2024 Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	29/04/24	409.05KB	Share
NOX	Tour de Cure Grant for Brain Cancer Research		04/04/24	217.52KB	Share
NOX	Appendix 4D and Half Year 2024 Financial Report	PRICE SENSITIVE	27/02/24	630.13KB	Share
NOX	Noxopharm extends Hudson Institute strategic partnership		13/02/24	219.18KB	Share
NOX	December 2023 Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	22/01/24	453.72KB	Share
NOX	Change of Director's Interest Notice - GM		18/12/23	4.51KB	Share
NOX	Notification of cessation of securities - NOX		18/12/23	21.54KB	Share
NOX	Results of Meeting		16/11/23	277.94KB	Share
NOX	Noxopharm Enhances Cash Position via R&D Rebate	PRICE SENSITIVE	16/11/23	199.04KB	Share
NOX	Noxopharm 2023 AGM Corporate Presentation	PRICE SENSITIVE	16/11/23	1.91MB	Share
NOX	Noxopharm 2023 AGM Chair Address		16/11/23	228.19KB	Share
NOX	Unlisted Options Expiring on 16 December 2023		27/10/23	187.41KB	Share
NOX	mRNA Vaccine Enhancer Shows Inflammation Reduction	PRICE SENSITIVE	18/10/23	386.06KB	Share
NOX	September 2023 Activities Report and Appendix 4C	PRICE SENSITIVE	13/10/23	486.21KB	Share
NOX	Response to ASX Query	PRICE SENSITIVE	09/10/23	373.25KB	Share
NOX	US FDA grants Orphan Drug Designation for CRO-67	PRICE SENSITIVE	04/10/23	202.75KB	Share
NOX	Trading Halt	PRICE SENSITIVE	03/10/23	254.24KB	Share
NOX	Pause in Trading	PRICE SENSITIVE	03/10/23	116.2KB	Share
NOX	Latest CRO-67 data shows success in reducing cancer growth	PRICE SENSITIVE	28/09/23	259.53KB	Share
NOX	2023 AGM Notice of Meeting and Proxy		28/09/23	531.07KB	Share
NOX	2023 AGM Letter to Shareholders and Proxy		28/09/23	508.77KB	Share
NOX	Annual Report to shareholders		27/09/23	9.17MB	Share
NOX	Change of Director's Interest Notice - FB		21/09/23	4.09KB	Share
NOX	Change of Director's Interest Notice - FB		18/09/23	4.11KB	Share
NOX	Appendix 4E and Audited Financial Statements	PRICE SENSITIVE	31/08/23	1.27MB	Share
NOX	Appendix 4G and Corporate Governance Statement		31/08/23	745.79KB	Share
NOX	Notification of cessation of securities - NOX		24/07/23	22.35KB	Share
NOX	June 2023 Activities Report and Appendix 4C	PRICE SENSITIVE	14/07/23	486.75KB	Share
NOX	Upcoming Expiry of Listed Options (ASX Code NOXOA)		05/07/23	1012.17KB	Share
NOX	Unlisted Options expiring on 23 July 2023		05/07/23	184.14KB	Share
NOX	Notification of cessation of securities - NOX		05/07/23	22.2KB	Share
NOX	Change of Director's Interest Notice - FB		03/07/23	4.1KB	Share
NOX	Change of Director's Interest Notice - FB		29/06/23	4.5KB	Share
NOX	Change of Director's Interest Notice - FB		19/06/23	4.76KB	Share
NOX	Change of Director's Interest Notice - BP		19/06/23	5.64KB	Share
NOX	Change of Director's Interest Notice - PM		19/06/23	4.48KB	Share
NOX	Details of Company Address		19/06/23	179KB	Share
NOX	IONIC Trial Abstract Published at ASCO	PRICE SENSITIVE	26/05/23	212.18KB	Share
NOX	Study results show new Sofra drug reduces inflammation	PRICE SENSITIVE	19/05/23	334.35KB	Share
NOX	Innovative Sofra research presented at European event		18/05/23	228.22KB	Share
NOX	Change of Director's Interest Notice - FB		10/05/23	4.76KB	Share
NOX	Upcoming Expiry of Listed Options (ASX Code NOXO)		08/05/23	1012.83KB	Share
NOX	Change of Director's Interest Notice - FB		04/05/23	4.77KB	Share
NOX	March 2023 Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	24/04/23	480.76KB	Share
NOX	Noxopharm to Prioritise Cutting-Edge Chroma & Sofra Programs	PRICE SENSITIVE	06/04/23	227.76KB	Share
NOX	Noxopharm Announces Novel mRNA Vaccine Enhancer	PRICE SENSITIVE	28/03/23	252.68KB	Share
NOX	Appendix 4D and Half Year 2023 Financial Report	PRICE SENSITIVE	24/02/23	650.49KB	Share
NOX	Noxopharm to Present Sofra Study at LUPUS 2023 Conference		22/02/23	206.12KB	Share
NOX	December 2022 Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	27/01/23	496.31KB	Share
NOX	DARRT-2 Trial Efficacy Phase to Commence	PRICE SENSITIVE	17/01/23	199.22KB	Share
NOX	NOX Pipeline Boosted by $1.5M Grant to Hudson Institute	PRICE SENSITIVE	16/12/22	213.48KB	Share
NOX	Change of Director's Interest Notice - FB		15/12/22	5.86KB	Share
NOX	Notification of cessation of securities - NOX		15/12/22	21.63KB	Share
NOX	Federal Innovation Connections Grant Awarded		06/12/22	196.29KB	Share
NOX	IONIC Trial Progresses as Veyonda Passes Safety Milestone		02/12/22	198.71KB	Share
NOX	Notification of cessation of securities - NOX		21/11/22	21.63KB	Share
NOX	Constitution		17/11/22	897.01KB	Share
NOX	Results of Meeting		17/11/22	241.56KB	Share
NOX	Noxopharm 2022 AGM Corporate Presentation		17/11/22	1.97MB	Share
NOX	Noxopharm AGM 2022 Chair's Address		17/11/22	196.06KB	Share
NOX	CEP-2 Safety Milestone Shows Veyonda Progress		16/11/22	200.28KB	Share
NOX	Noxopharm Enhances Cash Position via R&D Rebate	PRICE SENSITIVE	10/11/22	190.1KB	Share
NOX	Change in substantial holding		25/10/22	520.23KB	Share
NOX	September 2022 Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	21/10/22	476.23KB	Share
NOX	2022 AGM Notice of Meeting and Proxy		18/10/22	886.82KB	Share
NOX	2022 AGM Letter to Shareholders and Proxy		18/10/22	671.41KB	Share
NOX	Unlisted Options Expiring on 21 November 2022		07/10/22	178.47KB	Share
NOX	Noxopharm 2022 Annual Report		26/09/22	2.75MB	Share
NOX	Final Director's Interest Notice - GK		20/09/22	3.74KB	Share
NOX	Resignation of Dr Graham Kelly as Non-Executive Director		19/09/22	194.04KB	Share
NOX	Novel Dual-cell Therapy Results in Pancreatic Cancer	PRICE SENSITIVE	14/09/22	1.16MB	Share
NOX	Response to ASX Price Query (Correction to ASX Ticker)		02/09/22	170.47KB	Share
NOX	Response to ASX Price Query	PRICE SENSITIVE	02/09/22	272.24KB	Share
NOX	Appendix 4E and Audited Financial Statements	PRICE SENSITIVE	25/08/22	1.27MB	Share
NOX	Appendix 4G and Corporate Governance Statement		25/08/22	2.05MB	Share
NOX	Noxopharm & UNSW Pancreatic Cancer Research at US Conference		16/08/22	250.2KB	Share
NOX	CEP-2 Trial Passes Safety Milestone		09/08/22	195.92KB	Share
NOX	DARRT-2 Trial Safety Milestone and European Site Activated		02/08/22	195.39KB	Share
NOX	June 2022 Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	27/07/22	464.3KB	Share
NOX	Mayo Clinic and Washington Uni Join Noxopharm Sarcoma Trial		05/07/22	201.67KB	Share
NOX	$1.45M Grant to Hudson Institute for Noxopharm Collaboration		22/06/22	243.4KB	Share
NOX	HIMR Collaboration Secures mRNA Vic Acceleration Fund Grant		14/06/22	233.69KB	Share
NOX	Noxopharm Corporate Presentation		07/06/22	1.86MB	Share
NOX	Veyonda Abstract Published at ASCO Annual Meeting 2022		27/05/22	192.46KB	Share
NOX	March 2022 Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	28/04/22	564.87KB	Share
NOX	Orphan Drug Designation Granted to Noxopharm by US FDA	PRICE SENSITIVE	22/03/22	215.28KB	Share
NOX	First Patient Treated in CEP-2 Sarcoma Trial	PRICE SENSITIVE	28/02/22	200.85KB	Share
NOX	Appendix 4D and Half Year 2022 Financial Report	PRICE SENSITIVE	21/02/22	886.87KB	Share
NOX	Initial Director's Interest Notice - GM		01/02/22	132.87KB	Share
NOX	December 2021 Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	27/01/22	562.88KB	Share
NOX	Noxopharm Presents at H.C. Wainwright BioConnect Conference		10/01/22	2.49MB	Share
NOX	Noxopharm Receives A$5.865M R & D Tax Rebate	PRICE SENSITIVE	07/01/22	193.17KB	Share
NOX	Noxopharm Announces Leadership Transition	PRICE SENSITIVE	05/01/22	221.31KB	Share
NOX	Noxopharm DARRT-2 Cancer Trial Update	PRICE SENSITIVE	14/12/21	211.72KB	Share
NOX	Notification of cessation of securities - NOX		02/12/21	21.65KB	Share
NOX	Change of Director's Interest Notice - GK		02/12/21	228.55KB	Share
NOX	Noxopharm Annual General Meeting Results		17/11/21	217.19KB	Share
NOX	Licencing Deal Expands Noxopharm Drug Opportunities	PRICE SENSITIVE	17/11/21	331.4KB	Share
NOX	Noxopharm 2021 AGM Corporate Presentation		17/11/21	2.88MB	Share
NOX	Noxopharm 2021 AGM Chairmans Address		17/11/21	328.59KB	Share

NOX March 2024 Quarterly Activities Report and Appendix 4C
29/04/24	PRICE SENSITIVE	409.05KB	Share
NOX Tour de Cure Grant for Brain Cancer Research
04/04/24		217.52KB	Share
NOX Appendix 4D and Half Year 2024 Financial Report
27/02/24	PRICE SENSITIVE	630.13KB	Share
NOX Noxopharm extends Hudson Institute strategic partnership
13/02/24		219.18KB	Share
NOX December 2023 Quarterly Activities Report and Appendix 4C
22/01/24	PRICE SENSITIVE	453.72KB	Share
NOX Change of Director's Interest Notice - GM
18/12/23		4.51KB	Share
NOX Notification of cessation of securities - NOX
18/12/23		21.54KB	Share
NOX Results of Meeting
16/11/23		277.94KB	Share
NOX Noxopharm Enhances Cash Position via R&D Rebate
16/11/23	PRICE SENSITIVE	199.04KB	Share
NOX Noxopharm 2023 AGM Corporate Presentation
16/11/23	PRICE SENSITIVE	1.91MB	Share
NOX Noxopharm 2023 AGM Chair Address
16/11/23		228.19KB	Share
NOX Unlisted Options Expiring on 16 December 2023
27/10/23		187.41KB	Share
NOX mRNA Vaccine Enhancer Shows Inflammation Reduction
18/10/23	PRICE SENSITIVE	386.06KB	Share
NOX September 2023 Activities Report and Appendix 4C
13/10/23	PRICE SENSITIVE	486.21KB	Share
NOX Response to ASX Query
09/10/23	PRICE SENSITIVE	373.25KB	Share
NOX US FDA grants Orphan Drug Designation for CRO-67
04/10/23	PRICE SENSITIVE	202.75KB	Share
NOX Trading Halt
03/10/23	PRICE SENSITIVE	254.24KB	Share
NOX Pause in Trading
03/10/23	PRICE SENSITIVE	116.2KB	Share
NOX Latest CRO-67 data shows success in reducing cancer growth
28/09/23	PRICE SENSITIVE	259.53KB	Share
NOX 2023 AGM Notice of Meeting and Proxy
28/09/23		531.07KB	Share
NOX 2023 AGM Letter to Shareholders and Proxy
28/09/23		508.77KB	Share
NOX Annual Report to shareholders
27/09/23		9.17MB	Share
NOX Change of Director's Interest Notice - FB
21/09/23		4.09KB	Share
NOX Change of Director's Interest Notice - FB
18/09/23		4.11KB	Share
NOX Appendix 4E and Audited Financial Statements
31/08/23	PRICE SENSITIVE	1.27MB	Share
NOX Appendix 4G and Corporate Governance Statement
31/08/23		745.79KB	Share
NOX Notification of cessation of securities - NOX
24/07/23		22.35KB	Share
NOX June 2023 Activities Report and Appendix 4C
14/07/23	PRICE SENSITIVE	486.75KB	Share
NOX Upcoming Expiry of Listed Options (ASX Code NOXOA)
05/07/23		1012.17KB	Share
NOX Unlisted Options expiring on 23 July 2023
05/07/23		184.14KB	Share
NOX Notification of cessation of securities - NOX
05/07/23		22.2KB	Share
NOX Change of Director's Interest Notice - FB
03/07/23		4.1KB	Share
NOX Change of Director's Interest Notice - FB
29/06/23		4.5KB	Share
NOX Change of Director's Interest Notice - FB
19/06/23		4.76KB	Share
NOX Change of Director's Interest Notice - BP
19/06/23		5.64KB	Share
NOX Change of Director's Interest Notice - PM
19/06/23		4.48KB	Share
NOX Details of Company Address
19/06/23		179KB	Share
NOX IONIC Trial Abstract Published at ASCO
26/05/23	PRICE SENSITIVE	212.18KB	Share
NOX Study results show new Sofra drug reduces inflammation
19/05/23	PRICE SENSITIVE	334.35KB	Share
NOX Innovative Sofra research presented at European event
18/05/23		228.22KB	Share
NOX Change of Director's Interest Notice - FB
10/05/23		4.76KB	Share
NOX Upcoming Expiry of Listed Options (ASX Code NOXO)
08/05/23		1012.83KB	Share
NOX Change of Director's Interest Notice - FB
04/05/23		4.77KB	Share
NOX March 2023 Quarterly Activities Report and Appendix 4C
24/04/23	PRICE SENSITIVE	480.76KB	Share
NOX Noxopharm to Prioritise Cutting-Edge Chroma & Sofra Programs
06/04/23	PRICE SENSITIVE	227.76KB	Share
NOX Noxopharm Announces Novel mRNA Vaccine Enhancer
28/03/23	PRICE SENSITIVE	252.68KB	Share
NOX Appendix 4D and Half Year 2023 Financial Report
24/02/23	PRICE SENSITIVE	650.49KB	Share
NOX Noxopharm to Present Sofra Study at LUPUS 2023 Conference
22/02/23		206.12KB	Share
NOX December 2022 Quarterly Activities Report and Appendix 4C
27/01/23	PRICE SENSITIVE	496.31KB	Share
NOX DARRT-2 Trial Efficacy Phase to Commence
17/01/23	PRICE SENSITIVE	199.22KB	Share
NOX NOX Pipeline Boosted by $1.5M Grant to Hudson Institute
16/12/22	PRICE SENSITIVE	213.48KB	Share
NOX Change of Director's Interest Notice - FB
15/12/22		5.86KB	Share
NOX Notification of cessation of securities - NOX
15/12/22		21.63KB	Share
NOX Federal Innovation Connections Grant Awarded
06/12/22		196.29KB	Share
NOX IONIC Trial Progresses as Veyonda Passes Safety Milestone
02/12/22		198.71KB	Share
NOX Notification of cessation of securities - NOX
21/11/22		21.63KB	Share
NOX Constitution
17/11/22		897.01KB	Share
NOX Results of Meeting
17/11/22		241.56KB	Share
NOX Noxopharm 2022 AGM Corporate Presentation
17/11/22		1.97MB	Share
NOX Noxopharm AGM 2022 Chair's Address
17/11/22		196.06KB	Share
NOX CEP-2 Safety Milestone Shows Veyonda Progress
16/11/22		200.28KB	Share
NOX Noxopharm Enhances Cash Position via R&D Rebate
10/11/22	PRICE SENSITIVE	190.1KB	Share
NOX Change in substantial holding
25/10/22		520.23KB	Share
NOX September 2022 Quarterly Activities Report and Appendix 4C
21/10/22	PRICE SENSITIVE	476.23KB	Share
NOX 2022 AGM Notice of Meeting and Proxy
18/10/22		886.82KB	Share
NOX 2022 AGM Letter to Shareholders and Proxy
18/10/22		671.41KB	Share
NOX Unlisted Options Expiring on 21 November 2022
07/10/22		178.47KB	Share
NOX Noxopharm 2022 Annual Report
26/09/22		2.75MB	Share
NOX Final Director's Interest Notice - GK
20/09/22		3.74KB	Share
NOX Resignation of Dr Graham Kelly as Non-Executive Director
19/09/22		194.04KB	Share
NOX Novel Dual-cell Therapy Results in Pancreatic Cancer
14/09/22	PRICE SENSITIVE	1.16MB	Share
NOX Response to ASX Price Query (Correction to ASX Ticker)
02/09/22		170.47KB	Share
NOX Response to ASX Price Query
02/09/22	PRICE SENSITIVE	272.24KB	Share
NOX Appendix 4E and Audited Financial Statements
25/08/22	PRICE SENSITIVE	1.27MB	Share
NOX Appendix 4G and Corporate Governance Statement
25/08/22		2.05MB	Share
NOX Noxopharm & UNSW Pancreatic Cancer Research at US Conference
16/08/22		250.2KB	Share
NOX CEP-2 Trial Passes Safety Milestone
09/08/22		195.92KB	Share
NOX DARRT-2 Trial Safety Milestone and European Site Activated
02/08/22		195.39KB	Share
NOX June 2022 Quarterly Activities Report and Appendix 4C
27/07/22	PRICE SENSITIVE	464.3KB	Share
NOX Mayo Clinic and Washington Uni Join Noxopharm Sarcoma Trial
05/07/22		201.67KB	Share
NOX $1.45M Grant to Hudson Institute for Noxopharm Collaboration
22/06/22		243.4KB	Share
NOX HIMR Collaboration Secures mRNA Vic Acceleration Fund Grant
14/06/22		233.69KB	Share
NOX Noxopharm Corporate Presentation
07/06/22		1.86MB	Share
NOX Veyonda Abstract Published at ASCO Annual Meeting 2022
27/05/22		192.46KB	Share
NOX March 2022 Quarterly Activities Report and Appendix 4C
28/04/22	PRICE SENSITIVE	564.87KB	Share
NOX Orphan Drug Designation Granted to Noxopharm by US FDA
22/03/22	PRICE SENSITIVE	215.28KB	Share
NOX First Patient Treated in CEP-2 Sarcoma Trial
28/02/22	PRICE SENSITIVE	200.85KB	Share
NOX Appendix 4D and Half Year 2022 Financial Report
21/02/22	PRICE SENSITIVE	886.87KB	Share
NOX Initial Director's Interest Notice - GM
01/02/22		132.87KB	Share
NOX December 2021 Quarterly Activities Report and Appendix 4C
27/01/22	PRICE SENSITIVE	562.88KB	Share
NOX Noxopharm Presents at H.C. Wainwright BioConnect Conference
10/01/22		2.49MB	Share
NOX Noxopharm Receives A$5.865M R & D Tax Rebate
07/01/22	PRICE SENSITIVE	193.17KB	Share
NOX Noxopharm Announces Leadership Transition
05/01/22	PRICE SENSITIVE	221.31KB	Share
NOX Noxopharm DARRT-2 Cancer Trial Update
14/12/21	PRICE SENSITIVE	211.72KB	Share
NOX Notification of cessation of securities - NOX
02/12/21		21.65KB	Share
NOX Change of Director's Interest Notice - GK
02/12/21		228.55KB	Share
NOX Noxopharm Annual General Meeting Results
17/11/21		217.19KB	Share
NOX Licencing Deal Expands Noxopharm Drug Opportunities
17/11/21	PRICE SENSITIVE	331.4KB	Share
NOX Noxopharm 2021 AGM Corporate Presentation
17/11/21		2.88MB	Share
NOX Noxopharm 2021 AGM Chairmans Address
17/11/21		328.59KB	Share

REFRESH

1 2 3 4 5 6

(20min delay)
Last 6.6¢		Change 0.002(3.13%)		Mkt cap ! $19.28M

Open	High	Low	Value	Volume
6.6¢	6.6¢	6.6¢	$1.313K	19.89K

Buyers (Bids)

No.	Vol.	Price($)
1	100000	6.7¢

Sellers (Offers)

Price($)	Vol.	No.
6.8¢	14925	1

View Market Depth

No.	Vol.	Price($)
1	100000	0.067
2	229705	0.066
1	110000	0.065
4	232746	0.060
1	86207	0.058

Price($)	Vol.	No.
0.068	14925	1
0.069	30000	1
0.070	12000	1
0.071	14084	1
0.072	88899	1

Last trade - 11.32am 29/04/2024 (20 minute delay)


Last 6.6¢		Change 0.002 ( 0.00 %)
Open	High	Low	Volume
6.9¢	6.9¢	6.6¢	47961
Last updated 11.00am 29/04/2024 ?

NOX (ASX) Chart

NOXOPHARM LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available